Featured Research

from universities, journals, and other organizations

Popular diabetes drugs associated with fractures in type 2 diabetic patients, study finds

Date:
August 9, 2010
Source:
The Endocrine Society
Summary:
Postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures, according to a new study. Men with diabetes taking both loop diuretics and TZDs may also be at increased risk of fractures.

Postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Men with diabetes taking both loop diuretics and TZDs may also be at increased risk of fractures.

"Our study shows that increased fracture risk is associated with higher TZD dose, but no difference between rosiglitazone and pioglitazone is apparent suggesting a class effect of TZDs on fracture risk," said William Herman, MD, MPH, of the University of Michigan in Ann Arbor and senior author of the study. "Physicians should be aware of this risk and weigh the benefits and risks of therapy when they initially prescribe or renew prescriptions for TZDs."

Using data from Translating Research into Action for Diabetes (TRIAD), a multi-center prospective observational study of diabetes care in managed care, researchers conducted a matched case-control study to assess the odds of TZD exposure in patients with type 2 diabetes with and without fractures. From the study, researchers identified 786 cases of fractures and 2,657 matched controls (diabetes patients without fractures).

Women aged 50 years and older with fractures, when compared to their matched controls, were significantly more likely to have filled prescriptions for TZDs. Men with fractures were more likely to have filled prescriptions for TZDs and loop diuretics when compared to their matched controls. This result is particularly interesting because in men, loop diuretics or TZDs alone did not confer significant risks.

"Future studies, particularly long-term, prospective randomized clinical trials will be needed to conclusively demonstrate small to moderate harm," said Herman.

Other researchers working on the study include: Doris Bilik, Laura McEwen, Morton Brown, Catherine Kim, Keiko Asao, Victoria Hsiao and Pearl Lee of the University of Michigan in Ann Arbor; Nathan Pomeroy of the Center for Diabetes and Endocrinology in Grand Rapids, Mich.; Jesse Crosson of UMDNJ-Robert Wood Johnson Medical School in Somerset, N.J.; O. Kenrik Duru of the University of California in Los Angeles; Assiamira Ferrara, Andrew Karter and Joe Selby of Kaiser Permanente in Oakland, Calif.; and David Marrero and Usha Subramanian of Indiana University School of Medicine in Indianapolis.

The article, "Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes (TRIAD)," will appear in the October 2010 issue of JCEM.


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Popular diabetes drugs associated with fractures in type 2 diabetic patients, study finds." ScienceDaily. ScienceDaily, 9 August 2010. <www.sciencedaily.com/releases/2010/07/100729074907.htm>.
The Endocrine Society. (2010, August 9). Popular diabetes drugs associated with fractures in type 2 diabetic patients, study finds. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2010/07/100729074907.htm
The Endocrine Society. "Popular diabetes drugs associated with fractures in type 2 diabetic patients, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/07/100729074907.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins